Background Reliable and timely information on the leading causes of death in populations,
and how these are changing, is a crucial input into health policy debates. In the Global …

Objective: To develop evidence based recommendations for the management of gout. Methods:
The multidisciplinary guideline development group comprised 19 rheumatologists and …

Background New drugs and new evidence concerning the use of established treatments have
become available since the publication of the first European League Against Rheumatism …

… Perez-Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000
each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea. Dr. Lioté …

Background Measurement of the global burden of disease with disability-adjusted life-years
(DALYs) requires disability weights that quantify health losses for all non-fatal …

… Perez-Ruiz has received consulting fees, speaking fees, and/or honoraria from AstraZeneca,
Menarini, Pfizer, and CymaBay (less than $10,000 each). Dr. Saag has received consulting …

… Perez-Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000
each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea. Dr. Lioté …

Objectives To agree terminology and to develop recommendations for the diagnosis of calcium
pyrophosphate deposition (CPPD). Methods The European League Against Rheumatism …

Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout -
Perez‐Ruiz - 2002 - Arthritis Care & Research - Wiley Online Library … Fernando Perez-Ruiz …

Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for
hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular …